Table 3.

Diagnostic performance of urinary soluble CD163, serum and urinary soluble CD25, and conventional markers for detecting relapsing ANCA-associated GN

MarkersCutoffSamples: Active ANCA-Associated GN/All AvailableArea under the Curve [95% Confidence Interval]SensitivitySpecificityPositive Predictive ValueNegative Predictive ValuePositive Likelihood Ratio Weighted for PrevalenceNegative Likelihood Ratio Weighted for Prevalence
AKI47/570.66 [0.48 to 0.83]0.510.800.920.2612.022.89
New-onset hematuria45/550.58 [0.38 to 0.78]0.670.500.860.256.022.97
Proteinuria0.60 g/d47/580.78 [0.64 to 0.91]0.680.820.940.3816.111.66
AKI with hematuria and/or proteinuria47/570.75 [0.59 to 0.92]0.700.800.940.3616.501.77
C-reactive protein >10 mg/L47/570.62 [0.43 to 0.81]0.640.600.880.267.542.83
Urinary soluble CD16330 ng/mmol47/580.94 [0.88 to 1.00]0.940.910.980.7844.530.28
Serum soluble CD251350 ng/L46/570.61 [0.42 to 0.79]0.350.910.940.2516.583.05
Urinary soluble CD25210 ng/mmol47/580.50 [0.31 to 0.69]0.320.820.880.227.433.47
Urinary soluble CD163 with serum and urinary soluble CD2546/570.92 [0.82 to 1.00]0.940.910.980.7843.670.28
  • In total, 58 patients suspect of having relapsing ANCA-associated GN were used.